To validate the predictive value of the data obtained from SWE, AUROCs were calculated for baseline tumor LS values in predicting PD after treatment with anti-PD-1 antibodies plus lenvatinib; we found that the AUROC was increased in both the training and validation sets compared with the normal liver tissue. This evidence concerns the gene PDCD1 and neoplasm.